Weiwei Li

age ~51

from Carlsbad, CA

Get Report

Also known as:

Wei W Li
Li Weiwei

Connected to:

Weiwei Li Phones & Addresses

Carlsbad, CA
Dunlap, IL
Monterey Park, CA
La Puente, CA
Pasadena, CA
La Jolla, CA
La Puente, CA
Alhambra, CA

Resumes

Principal Engineer

view source

Location:

Carlsbad, CA

Industry:

Machinery

Work:

Nordson Asymtek
Principal Engineer
Asymtek
Senior Staff Engineer
Caterpillar Inc. 2006 - 2008
Research Engineer
University of California, San Diego 2000 - 2006
Research Assistant

Education:

Uc San Diego 2000 - 2006
Doctorates, Doctor of Philosophy Beijing Institute of Control Engineering 1994 - 1997
Master of Science, Masters Xidian University 1990 - 1994
Bachelors, Bachelor of Science, Electrical Engineering

Skills:

Simulink
Simulations
Algorithms
Embedded Systems
Control Systems Design
Matlab
Control Theory
C++
Robotics
Electronics
Automation
Signal Processing
Firmware
C
Hev
Electric Vehicles
System Identification

Weiwei Li

view source

Us Patents

Methods And Compositions Related To Targeting Monoacylglycerol Lipase
view source
US Patent:

20110275650, Nov 10, 2011
Filed:

Nov 10, 2009
Appl. No.:

12/998642
Inventors:

Benjamin F. Cravatt - La Jolla CA, US
Jonathan Z. Long - Solana Beach CA, US
Weiwei Li - Sunnyvale CA, US
Daniel K. Nomura - La Jolla CA, US
Assignee:

THE SCRIPPS RESEARCH INSTITUTE - LA JOLLA CA
International Classification:

A61K 31/4418
C07D 405/14
C07D 295/155
A61K 31/443
A61K 31/495
A61P 25/00
A61P 29/00
A61P 25/24
A61P 25/22
A61P 9/00
A61P 3/00
A61P 25/28
A61P 27/06
A61P 35/00
C12N 5/09
C07D 213/56
US Classification:

51425501, 546335, 5462837, 544389, 514357, 514338, 435375
Abstract:

This invention provides compounds that selectively inhibit monoacylglycerol lipase (MAGL). The invention also provides methods of using the MAGL selective inhibitors to stimulate 2-Arachidonoylglycerol (2-AG) mediated endocannabinoid signaling in vivo, and to treat conditions that are associated with or linked to endocannabinoid signaling. The invention additionally provides methods of treating cancer or inhibiting tumor growth by targeting MAGL with MAGL specific inhibitors. The invention further provides methods of screening for MAGL inhibitors with improved biochemical and pharmaceutical properties.

Anti-Cancer Serine Hydrolase Inhibitory Carbamates
view source
US Patent:

20130281453, Oct 24, 2013
Filed:

Oct 21, 2011
Appl. No.:

13/881884
Inventors:

Benjamin Cravatt - La Jolla CA, US
Daniel Nomura - San Diego CA, US
Jae W. Chang - La Jolla CA, US
Raymond E. Moellering - La Jolla CA, US
Weiwei Li - San Diego CA, US
Assignee:

The Scripps Research Institute - La Jolla CA
International Classification:

C07D 409/12
C07D 307/87
C07D 333/24
C07C 271/46
C07C 271/48
C07D 405/12
C07C 271/44
C07D 207/337
US Classification:

5142355, 560 28, 514481, 435184, 435 29, 506 11, 549462, 514469, 548563, 514427, 560 31, 560 29, 548527, 514422, 548526, 549 77, 514438, 544141
Abstract:

Serine hydrolases are implicated in malconditions such as cancer, central nervous system disorders, cardiovascular disorders, obesity, and metabolic disorders. Many serine hydrolases expressed in proteomic libraries are of unknown function in vivo. Compounds identified through library versus library screening can be used for treatment of malconditions associated with the specific serine hydrolase KIAA1363 (also known as AADACL1). A library of inhibitors of KIAA1363 was prepared and candidate compounds were identified as a potent inhibitors having submicromolar ICvalues. An exemplary compound of the invention was shown to be an effective inhibitor of prostate cancer pathogenesis. Other inhibitory compounds of the invention comprising fluorophore groups are shown to be effective in spatial and temporal localization of the serine hydrolase in cells and tissues.